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Computer Science, Texas A&M University-Commerce, Commerce, Texas, USAIntroduction: The survival beneﬁt from simultaneous liver-kidney transplantation (SLK) over liver trans-
plant alone (LTA) in recipients with moderate renal dysfunction is not well understood. Moreover, the
impact of deceased donor organ quality in SLK survival has not been well described in the literature.
Methods: The Scientiﬁc Registry of Transplant Recipients was studied for adult recipients receiving LTA
(N ¼ 2700) or SLK (N ¼ 1361) with moderate renal insufﬁciency between 2003 and 2013. The study cohort
was stratiﬁed into 4 groups based on serum creatinine (<2 mg/dl versus $2 mg/dl) and dialysis status at
listing and transplant. The patients with end-stage renal disease and requiring acute dialysis more than 3
months before transplantation were excluded. A propensity score matching was performed in each
stratiﬁed group to factor out imbalances between the SLK and LTA regarding covariate distribution and to
reduce measured confounding. Donor quality was assessed with liver donor risk index. The primary
outcome of interest was posttransplant mortality.
Results: In multivariable propensity score-matched Cox proportional hazard models, SLK led to decrease
in posttransplant mortality compared with LTA across all 4 groups, but only reached statistical signiﬁcance
(hazard ratio 0.77; 95% conﬁdence interval, 0.62–0.96) in the recipients not exposed to dialysis and serum
creatinine $ 2 mg/dl at transplant (mortality incidence rate per patient-year 5.7% in SLK vs. 7.6% in LTA,
P ¼ 0.005). The decrease in mortality was observed among SLK recipients with better quality donors
(liver donor risk index < 1.5).
Discussion: Exposure to pretransplantation dialysis and donor quality affected overall survival among SLK
recipients.
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International Reports (2016) 1, 221–229creatinine (Scr) and dialysis dependence signiﬁcantly
impact wait-list mortality for liver transplant candidates
as impaired kidney function is heavily weighted in the
MELD score calculation.1,2 The guidelines for dual organ
distribution have changed several times since 2007, and
the allocation process currently allows a kidney to be
offered to any liver candidate based onmedical necessity
and local transplant physician opinion.2–5 These changes
in the distribution system have resulted in different
organ utilization practices among transplant centers.2221
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patients with decompensated cirrhosis and end-stage
renal disease (ESRD)6–8 as the reported survival is
similar to liver transplant alone (LTA) recipients
without renal dysfunction. However, the recom-
mended SLK criteria do not provide clear guidelines
concerning transplant recipients with acute kidney
injury (AKI) requiring renal replacement therapy (<3
months) and AKI superimposed on chronic kidney
disease (CKD). The parameters for optimal stratiﬁcation
of these transplant candidates (SLK vs. LTA) remain
unclear, and conﬂicting data have failed to describe the
patient survival beneﬁt among transplant recipients
with moderate renal dysfunction.6,9,10
It is well known that donor and recipient charac-
teristics predict graft survival.11,12 Standardized mea-
sures for assessing donor quality (liver donor risk
index [L-DRI]) and the recipient’s pretransplant mor-
tality risk (MELD score) have helped optimize trans-
plant survival, which is essential given the scarce
organ supply.13 However, few studies have evaluated
the impact of organ quality on mortality especially
among high-risk donors (L-DRI > 1.5) for patients
seeking SLK allocation.14,15
In this study, we aimed to evaluate the survival
beneﬁt of SLK over LTA among propensity score (PS)-
matched liver transplant recipients with moderate renal
dysfunction. We stratiﬁed our study cohort into 4
groups deﬁned by kidney function and dialysis status at
listing and transplantation. The predictive models esti-
mating mortality were performed within each stratum.
We also examined donor quality on posttransplant
mortality in SLK recipients, as measured by L-DRI.
MATERIALS AND METHODS
Study Cohort and Design
This study used data from the Scientiﬁc Registry of
Transplant Recipients (SRTR). The SRTR data system is
a national database that includes data on all donors,
wait-listed candidates, and transplant recipients in the
USA, submitted by the members of the Organ Pro-
curement and Transplantation Network (OPTN). The
Health Resources and Services Administration and US
Department of Health and Human Services provide
oversight to the activities of the OPTN and SRTR
contractors.
This study was a retrospective cohort analysis of the
OPTN/United Network for Organ Sharing Registry and
included all adults who underwent liver trans-
plantation between January 2003 and September 2013
in the USA (N ¼ 72,323). Figure 1 illustrates the se-
lection of study cohort. Exclusion criteria included the
following: (i) liver transplant recipients who received
exception points for any reason (e.g., hepatocellular222cancer), as these patients tend not to get SLK except in
the case of primary hyperoxaluria; (ii) status 1 recipients
(acute liver failure cases); (iii) pediatric patients (younger
than 18); (iv) multi-organ transplantations (other than
SLK); (v) diagnosis of ESRD before transplantation; and
(iv) acute dialysis that needs more than 3 months.
We stratiﬁed the recipients by their transplant type
(SLK being the primary exposure) into 4 different
groups based on Scr and dialysis status at listing and at
the time of transplant: LK1, not on dialysis either at
listing or transplant, and Scr < 2 mg/dl at transplant;
LK2, not on dialysis either at listing or transplant, and
Scr $ 2 mg/dl at transplant; LK3, not on dialysis at
listing but on dialysis at transplant; LK4, on dialysis
both at listing and at transplant. The cutoff value for
Scr was chosen from the recommendations of recent
transplant consensus conferences. Scr < 2 mg/dl
(approximately estimated glomerular ﬁltration rate
[eGFR] $ 30 ml/min per 1.73 m2, using the Modiﬁca-
tion of Diet in Renal Disease Study 4-variable equation)
versus Scr $ 2 mg/dl (approximate eGFR < 30 ml/min
per 1.73 m2), and the Chronic Liver Failure-Sequential
Organ Failure scoring deﬁnes renal failure as a Scr
of $ 2.3,4,16,17 The aim of our study is to ﬁnd the dif-
ferences between SLK and LTA regarding posttrans-
plant survival. For a meaningful comparison, it is
essential to consider imbalances between the SLK and
LTA regarding the covariate pattern. We adjusted for
imbalances among covariates by developing PS
matching within each stratum (LK1–LK4). A total of
4061 patients were included in the ﬁnal analysis.
Because of a sample size imbalance between the LTA
and SLK recipients within each LK group, we adopted
different matching ratios in the PS analysis (4:1 in the
LK1 group, 3:1 in the LK2 group, and 2:1 in the LK3
and LK4 groups).
Patients were followed up from the date of liver
transplant to posttransplant death, loss to follow-up, or
end of study period (30 September 2013). The primary
outcome of interest was posttransplant mortality. We
also investigated the effect of deceased donor quality on
posttransplantmortality in SLK patients, as measured by
L-DRI categories (L-DRI< 1, 1–1.5, 1.5–2, and>2). The
L-DRI score was derived from 6 donor characteristics
(age, cause of death, race, donation after cardiac death,
graft [whole vs. partial split], donor height [cm]) and 2
transplant factors (location of donor service area [local,
regional, and national] and cold ischemia time [hour]).
Most L-DRI scores range from 0 to 3.5, and lower scores
represent better quality liver (especially L-DRI < 1.2).
Statistical Analysis
Donor and recipient characteristics were described
using mean and SD or frequencies. ComparisonsKidney International Reports (2016) 1, 221–229
Figure 1. Strobe chart showing the selection of the study cohort. HCC, hepatocellular cancer; HPS, hepatopulmonary syndrome; LTA, liver
transplant alone; PPHTN, portapulmonary hypertension; PS matching, propensity score matching; Scr, serum creatinine; SLK, simultaneous
liver-kidney transplantation.
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Wallis test, or c2 test. Patient survival rates were
estimated using the Kaplan-Meier product limit
method. The log-rank test was used for comparison of
the unadjusted patient survival curves. Cox propor-
tional hazard regression models were used to estimate
the hazard ratios associated with patient mortality risk.
P value < 0.05 was considered statistically signiﬁcant.
Statistical analyses were performed with Stata/MP13
(StataCorp LP, College Station, TX). The magnitude of
missing data in the PS-matched cohort was minuscule
(1%–2% among covariates, speciﬁcally in ascites and
encephalopathy variables) and all models were directly
comparable. That is why we practically considered this
study as complete case analysis.
PS is a balancing score representing the probability
of receiving an SLK versus LTA given the patient’s
covariate pattern.18 After PS is estimated, the next step
involves matching exposure versus control (SLK vs.
LTA) patients based on predicted PSs. Within each
stratum (LK1–LK4), we used nearest-neighbor Maha-
lanobis metric matching with a bias correction termKidney International Reports (2016) 1, 221–229(http://www.stata.com/manuals13/teteffectsnnmatch.pdf)
tomatch and allocate patients to the respective groups. The
11 covariates used in the PS analysis included the re-
cipient’s age, gender, race, body mass index, diabetes,
underlying liver disease etiology, Scr (mg/dl) at transplant
(if a patient is on dialysis, Scr is omitted from the PS
analysis), serum bilirubin (mg/dl) at transplant, interna-
tional normalized ratio at transplant, time to transplant
(wait-list duration in months), and the L-DRI score. Sta-
tistical inference was based on the analysis within strata
deﬁned by kidney function and/or dialysis status using
multivariable PS-matched Cox proportional hazardmodels
adjusted for other covariates including ABO type, en-
cephalopathy, ascites, estimated slope of creatinine from
wait-listing to transplantation (for the LK1 and LK2 groups
only), hospitalized in ICU before transplant (onmechanical
ventilation), and transplant year.
RESULTS
Characteristics of the Study Cohort
Selected demographics and clinical characteristics for
LTA and SLK before PS matching are shown in Table 1.223
Table 1. Characteristics of liver transplant candidates before
propensity score matching by transplant type (UNOS data between
2003 and 2013 in the USA)
N LTA SLK P value
N ¼ 35,947 34,337 1610
Age (yr)a 35,947 52.6  10 54.3  9.6 <0.001
Gender (female, %)a 35,947 33.9 34.1 0.84
Race (AA, %)a 35,947 8.9 15.3 <0.001
Recipient DM (%)a 35,947 23.5 37 <0.001
Liver disease (%)a 35,947 <0.001
HCV infection 27.8 28.6
ETOH and NASH 23.6 23.4
Cholestatic 10.9 7
Others 37.6 40.1
BMIa 35,919 28.3  5.8 27.4  5.8 <0.001
Scr (mg/dl) at transplant
(if not on dialysis)a
34,403 1.5  1 3  1.2 <0.001
eGFR at transplant
(ml/min per 1.73 m2)b
34,403 62.9  32.5 26.9  17.2 <0.001
INR at transplanta 35,947 2  1.2 1.9  0.9 <0.001
Total bilirubin (mg/dl) at
transplanta
34,258 10.7  12 12.4  14.5 <0.001
On dialysis at transplant (%) 35,947 8.6 50 <0.001
MELD at transplant 35,944 24.2  9.2 30.9  8.4 <0.001
Liver DRIa 30,982 1.4  0.4 1.2  0.3 <0.001
Median time to transplant
(25th and 75th
percentiles), moa
35,946 1.9 (0.4, 6.8) 1.3 (0.4, 5.2) 0.001
 Denotes 1 SD.
AA, African American; BMI, body mass index; DM, diabetes; DRI, donor risk index;
eGFR, estimated glomerular ﬁltration rate; ETOH and NASH, alcohol and nonalcoholic
steatohepatitis; HCV, hepatitis C virus; INR, international normalized ratio; LTA, liver
transplant alone; MDRD, Modiﬁcation of Diet in Renal Disease Study; MELD, model for
end-stage liver disease; N, sample size; Scr, serum creatinine; SLK, simultaneous liver-
kidney transplantation; UNOS, United Network for Organ Sharing.
aThe variables used in the propensity score matching.
bThe MDRD 4-variable equation to eGFR, calculated for the recipient who was not on
dialysis.
CLINICAL RESEARCH B Tanriover et al.: Simultaneous Liver-Kidney AllocationCompared with LTA patients, SLK recipients had lower
GFR at transplant (62.9  32.5 ml/min per 1.73 m2 vs.
26.9  17.2 ml/min per 1.73 m2), more likely required
dialysis (8.6% vs. 50%), and tend to have a higher
MELD score at transplant (24.2  9.2 vs. 30.9  8.4).
After PS matching, the LK groups were well balanced
on the distribution of covariates (Supplementary
Tables S1a–S1d). The median waiting time to trans-
plantation was approximately 2 months in all groups
except the LK4 group (<1 month). The recipients in the
LK3 and LK4 groups had more severe disease on the
level of liver and kidney dysfunction.
Outcomes
Mortality
For the study cohort (after the PS matching), unad-
justed Kaplan-Meier curves for patient survival for
LTA versus SLK recipients are illustrated in Figure 2a–d.
The SLK recipients in the LK2 group had better
patient survival compared with the LTA patients (77%
vs. 70% at 5 years, P ¼ 0.01). Causes of death (reported
for liver recipients) and its observed frequencies by the
LK groups and posttransplant outcomes through the224end of follow-up time are shown in Table 2. Mortality
incidence rate per patient-year was lower in SLK
recipients across all LK groups, and the mortality inci-
dence rate ratio (SLK/LTA: 0.75, 0.60–0.92, P value ¼
0.005) reached statistical signiﬁcance in only the LK2
group.
In multivariable PS-matched Cox proportional haz-
ard models (Table 3), SLK resulted in a decrease in
posttransplant mortality compared with LTA across all
4 LK groups, but only reached statistical signiﬁcance
(hazard ratio, 0.77; 95% conﬁdence interval, 0.62–0.96)
in the recipients who were not exposed to dialysis and
Scr $ 2 mg/dl at transplant (LK2).
Renal Outcomes and Rate of ESRD
Compared with SLK recipients, posttransplant ESRD
was more prevalent in the LTA transplants, except LK1
group (Table 2). In SLK recipients, ESRD incidence rate
per 1000 patient-days and the incidence rate ratio (SLK/
LTA) were lower and reached statistical signiﬁcance in
the LK2 and LK4 groups. Kidney transplantation after
LTA or SLK was uncommon across all LK groups
(<3.2% of recipients).
Subgroup Analysis in SLK Recipients According to
L-DRI Categories
Figure 3 shows the unadjusted Kaplan-Meier curves for
patient survival according to L-DRI categories in SLK
recipients. Higher L-DRI scores were associated with
higher mortality. In a multivariable Cox proportional
hazard model adjusted for other covariates, posttrans-
plant mortality signiﬁcantly increased with more top
L-DRI categories (1.5–2 and >2 categories). For com-
parison, L-DRI categories of 1.5 to 2 and L-DRI > 2
approximately exemplify higher quintiles of kidney
donor proﬁle index, 60% to 80%, and 80% to 100%,
respectively (Table 4).
DISCUSSION
The prevalence of pretransplant renal dysfunction in
liver transplant recipients ranges between 15% and
30%.19,20 In addition, posttransplant ESRD portends
inferior outcomes for LTA recipients (5-year patient
survival in LTA: 80% in recipients without renal
dysfunction vs. 40% in recipients after onset of
ESRD).21–23 Short-term acute renal replacement therapy
(<3 months), in pre-LTA period, is associated with
relatively small (8.9%) nonrenal recovery at 6 months
after transplantation. The 5-year cumulative risk of
new-onset ESRD after LTA ﬂuctuates between 3% and
18% depending on “renal risk index” decile. Renal risk
index is a validated prognostic tool predicting post-
LTA ESRD risk based on 14 different factors at the
time of transplantation7,24 (https://rri.med.umich.edu).Kidney International Reports (2016) 1, 221–229
Figure 2. (a) Unadjusted Kaplan-Meier patient survival curves for liver transplant alone (LTA) versus simultaneous liver-kidney transplantations
(SLK) recipients not on dialysis either at listing or transplant, and serum creatinine <2 mg/dl at transplant (LK1), after the propensity score
matching (UNOS data between 2003 and 2013 in the USA). (b) Unadjusted Kaplan-Meier patient survival curves for LTA versus SLK recipients
not on dialysis either at listing or transplant and serum creatinine $2 mg/dl at transplant (LK2), after the propensity score matching (UNOS data
between 2003 and 2013 in the USA). (c) Unadjusted Kaplan-Meier patient survival curves for LTA versus SLK recipients not on dialysis at listing
but on dialysis at transplant (LK3), after the propensity score matching (UNOS data between 2003 and 2013 in the USA). (d) Unadjusted Kaplan-
Meier patient survival curves for LTA versus SLK recipients on dialysis at listing and transplant (LK4), after the propensity score matching (UNOS
data between 2003 and 2013 in the USA). UNOS, United Network for Organ Sharing.
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Survival Beneﬁt of SLK Over LTA
In the literature, single center reports have been un-
derpowered because of small sample sizes,10,20,25,26 and
comprehensive registry analyses have been limited due
to center-speciﬁc heterogeneity in transplant recipient
selection and differences in deﬁning AKI versus CKD.
Moreover, dialysis status and duration are not well
reported in the OPTN/UNOS or the SRTR data-
sets.6,9,27–29 Unsurprisingly, these studies have yielded
conﬂicting results concerning the independent pro-
tective effect of SLK on posttransplant survival. In a
recent publication, Sharma et al.5 analyzed the SRTR
data between 2002 and 2009 to study survival beneﬁt
of SLK (N ¼ 4283) over LTA (N ¼ 1326) in a PS- and
prognostic score-matched study cohort. For patientsKidney International Reports (2016) 1, 221–229not on dialysis, SLK offered 3.7 months’ survival
beneﬁt whereas only 1.4 months in recipients on dial-
ysis compared with LTA.5
Our study is one of the largest contemporary OPTN/
UNOS registry analyses in the post-MELD era that ex-
amines the survival beneﬁt of SLK and LTA when can-
didates are stratiﬁed into 4 groups according to the level
of renal insufﬁciency and dialysis status at listing and
transplant. We placed more emphasis on patient selec-
tion and established the PS matching to allow for
meaningful comparisons between SLK and LTA re-
cipients. The results of our study showed that signiﬁcant
survival beneﬁt (23% decrease in relative risk of mor-
tality) of SLK was limited to recipients not exposed to
dialysis but still hadmoderate renal dysfunction (Scr$ 2
mg/dl) at the time of transplant. We suspect that this225
Table 2. Causes (reported for liver transplant recipients) and observed frequencies of death and posttransplant outcomes after the propensity
score matching
Liver transplant recipients not
on dialysis either at listing or
transplant, and Scr < 2 mg/dl at
transplant (LK1)
Liver transplant recipients not on
dialysis either at listing or
transplant, and Scr ‡ 2 mg/dl at
transplant (LK2)
Liver transplant recipients not
on dialysis at listing but on
dialysis at transplant (LK3)
Liver transplant recipient on
dialysis both at listing and
transplant (LK4)
LTA SLK P LTA SLK P LTA SLK P LTA SLK P
N 536 144 1237 570 579 383 348 264
Posttransplant mortality
Incidence rate per patient-year (%) 5.7 4.7 7.6 5.7 9.2 7.4 10 8.4
Incidence rate ratio (95% CI) 0.81 (0.50–1.28) 0.38 0.75 (0.60–0.92) 0.005 0.81 (0.61–1.05) 0.10 0.84 (0.61–1.16) 0.28
Time to death (mo) 31  32 19  20 0.08 27  30 30  32 0.33 19  27 24  31 0.19 16  11 16  10 0.99
Causes of death reported for liver
transplantation (%)
0.09* 0.09* 0.10* 0.06*
Graft failure 14.4 11.1 13 11.1 9.4 13.1 12.5 7.4
CVS 13.6 14.8 18.6 17.1 22.7 16.7 17.9 7.4
Hemorrhage 6.8 0 5.1 0.9 4.7 0.0 6.3 5.9
Infection 14.4 33.3 21.5 25.6 31.3 27.4 23.2 41.2
Malignancy 14.4 11.1 9.8 9.4 7.8 7.2 9.8 8.8
Renal failure 5.1 14.8 9.5 4.3 7 3.6 11.6 4.4
Other 14.4 11.1 8.8 16.3 8.6 13.1 12.5 11.8
Unknown 17 3.7 13.7 15.4 8.6 19.1 6.3 13.4
Posttransplant ESRD
Incidence rate per 1000 patient-days 1.1 1.5 1.3 0.8 1.4 1.7 2.6 0.9
Incidence rate ratio 1.36 (0.62–2.79) 0.38 0.63 (0.43–0.89) 0.01 1.22 (0.74–2.00) 0.40 0.34 (0.16–0.69) 0.001
Kidney transplantation post-LTA or
post-SLK, n (%)
6 (1.1) 3 (2.1) 0.37 36 (2.9) 5 (0.9) 0.01 18 (3.1) 6 (1.6) 0.13 11 (3.2) 7 (2.6) 0.71
Liver retransplantation 20 (3.7) 4 (2.8) 0.58 50 (4) 14 (2.5) 0.09 23 (4) 11 (2.9) 0.37 10 (2.9) 8 (3) 0.91
CI, conﬁdence interval; CVS, cardiovascular system; ESRD, end-stage renal disease; LTA, liver transplant alone; Scr, serum creatinine; SLK, simultaneous liver-kidney transplantation.
*P value for trend (type III P value).
CLINICAL RESEARCH B Tanriover et al.: Simultaneous Liver-Kidney Allocationobserved reduction in posttransplant mortality rate is
likely related to a lower posttransplant ESRD incidence
rate. The posttransplant mortality rate exceeds the rate
of ESRD in patients exposed to dialysis before transplant
(LK3 and LK4) where the priority is primarily to obtain
optimal quality of liver to minimize mortality.
Compared with SLK recipients, posttransplant ESRD
was signiﬁcantly higher among LTA patients in the
LK2 (moderate CKD) and LK4 groups (AKI requiring
dialysis at listing and transplant), probably represent-
ing the lower chance of renal recovery. However, the
LTA patients with shorter dialysis exposure (LK3Table 3. Cox proportional hazard models for mortality among patients und
alone by strata deﬁned by renal function and dialysis status
Model
Liver transplant recipients not
on dialysis either at listing or
transplant, and Scr < 2 mg/dl
at transplant (LK1)
Liver transplan
on dialysis eit
transplant, an
at transp
HR (95% CI) P HR (95% C
Before propensity score matching
Missing data, % (missing/total N) 0.9 (234/26,209) 1.4 (82/597
Unadjusted model 0.83 (0.56–1.22) 0.34 0.83 (0.70–0
After propensity score matching
Missing data, % (missing/total N) 0.4 (3/680) 1.5 (27/180
Model adjusted for other covariatesa 0.88 (0.56–1.39) 0.59 0.77 (0.62–0
CI, conﬁdence interval; HR, hazard ratio; N, sample size; Scr, serum creatinine.
aOther covariates: ABO type, encephalopathy category, ascites category, estimated slope of cr
ICU before transplant (on mechanical ventilation), and transplant year.
226group) experienced similar ESRD and mortality inci-
dence rate compared with the SLK patients suggesting
signiﬁcant renal recovery posttransplantation.
Effect of Organ Quality on Mortality
There are limited data on the effect of donor quality on
mortality in liver transplant recipients when
comparing SLK with LTA. In their single-center study,
Levitsky et al.30 examined the rate of renal recovery
post-SLK (N ¼ 155) and found that patient and kidney
survival at 1 year was worse among SLK recipients who
received expanded criteria donors (59.5% for bothergoing simultaneous liver-kidney transplant versus liver transplant
t recipients not
her at listing or
d Scr ‡ 2 mg/dl
lant (LK2)
Liver transplant recipients not
on dialysis at listing but on
dialysis at transplant (LK3)
Liver transplant recipient on
dialysis both at listing and
transplant (LK4)
I) P HR (95% CI) P HR (95% CI) P
1) 2.5 (63/2551) 1.5 (18/1216)
.99) 0.04 0.92 (0.76–1.13) 0.42 1.04 (0.82–1.32) 0.73
7) 2.1 (20/962) 2.1 (13/612)
.96) 0.02 0.89 (0.68–1.16) 0.39 0.89 (0.64–1.23) 0.48
eatinine from wait-listing to transplantation (for the LK1 and LK2 groups), hospitalized to
Kidney International Reports (2016) 1, 221–229
Figure 3. Kaplan-Meier survival curves in SLK recipients in the USA
between January 2003 and September 2013, by L-DRI categories
(after the PS matching). L-DRI, liver donor risk index; PS matching,
propensity score matching; SLK, simultaneous liver-kidney
transplantation.
Table 4. Multivariable Cox proportional hazard model for
posttransplant mortality in simultaneous liver-kidney transplant
recipients by liver-donor risk index (L-DRI) categories, after the
propensity score matching
N [ 1341 Hazard ratioa 95% conﬁdence interval P value
L-DRI (reference L-DRI < 1)
1–1.5 1.07 0.81–1.42 0.64
1.5–2 2.00 1.44–2.79 <0.001
>2 3.75 2.03–6.93 <0.001
aAdjusted for the recipient factors (age, body mass index, race, gender, diabetes),
waiting time, the cause of liver disease, blood type, model for end-stage liver disease
at transplant encephalopathy at transplant, ascites on at transplant, mechanical
ventilation/ICU stay and transplant year, and transplant type.
B Tanriover et al.: Simultaneous Liver-Kidney Allocation CLINICAL RESEARCHoutcomes) compared with those who had non-ECD
donors (89% and 81%, respectively).30 In our study
cohort, before the PS matching across all groups, LTA
and SLK recipients were transplanted with signiﬁcantly
better quality organs (L-DRI # 1.2) and SLK patients
had lower liver disease severity (lower MELD scores) at
transplant. We observed that posttransplant mortality
signiﬁcantly increased with lower quality donors
(L-DRI > 1.5 or equivalent of kidney donor proﬁle index
> 60%). This SLK survival beneﬁt with higher quality
organs was described in another registry analysis.5
This study analysis generates several intertwined
ethical questions on fairness in kidney allocation: (i)
granting higher quality kidneys to SLK recipients; (ii)
unequal access to kidneys (shorter waiting time for
SLK, even though a kidney recipient may get equal
beneﬁt from the organ); (iii) permitting higher priority
to SLK recipients (multi-organ transplants receive
precedence over all kidney alone candidates, including
highly sensitized candidates and children); and (iv)
violation of the UNOS Final Rule (x 121.8 Allocation of
organs based on objective and measurable medical
criteria), as transplant centers currently decide who
gets SLK.
Given the shortcoming of the current allocation
system, in June 2016, the (OPTN/UNOS) Boards of
Directors approved a policy launching speciﬁc medical
eligibility criteria for candidates pursuing SLK trans-
plants. The new criteria include the following: (i) AKI
requiring dialysis support or having GFR < 25 ml/min
for more than 6 weeks; (ii) established CKD with GFR
< 35 ml/min at listing with preceding CKD stage 3
(eGFR < 60 ml/min at least 3 consecutive months); (iii)
metabolic diseases (primary hyperoxaluria, atypicalKidney International Reports (2016) 1, 221–229hemolytic uremic syndrome with factor H mutation,
familial systemic amyloidosis, or methylmalonic
aciduria); and (iv) allocation rules (expedited access
to deceased donor kidney transplantation for LTA
recipients with persistent dialysis need or GFR < 20
ml/min within the ﬁrst year of liver transplantation).31
Implementation of the policy may take more than a
year, and its potential effect on SLK allocation is yet to
be seen. Some researchers32,33 predict a reduction in
kidney allograft distribution (approximately 19%
decrease) to SLK transplants after the implementation
of this policy, whereas others predict an increase in
kidney utilization (twice as much in SLK number,
sharp increase from 550 to 920 annually).34
Kidney Utilization Conundrum in Liver
Transplant Candidates With Renal Dysfunction
in the Post-MELD Era
Kidney disease severity is one of the major de-
terminants of wait-list1,35 and postliver transplant
mortality.21,22,36 Nevertheless, it is heavily weighted in
the current MELD allocation system (overestimating
mortality risk),37 which assumes that liver transplant
candidates with identical MELD scores achieve similar
survival beneﬁt regardless of differences in the indi-
vidual components of the MELD score.15,38 However,
Sharma et al. demonstrated that, comparing mortality
rates between wait-list and postliver transplant, higher
Scr at the similar level of MELD scores was associated
with decreased survival beneﬁt (no signiﬁcant advan-
tage of liver transplantation for Scr > 2.5 mg/dl) across
different MELD score categories (15–17 and 24–40 at
transplant).39 They also observed similar results in re-
cipients on dialysis at transplant (no survival beneﬁt
for the MELD score > 27). These observations suggest
that the MELD-based allocation may be shifting mor-
tality risk from the wait-list to the posttransplant
period in liver recipients with renal dysfunction.
Remarkably, the results of our study, when matched
with severity of renal and liver disease, support pre-
vious reports concerning the inverse relationship227
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with SLK over LTA despite adding a renal transplant to
the equation.39–41
Strength and Limitations
Our study has limitations that are inherent in obser-
vational studies. Although we adjusted for various
covariates at baseline, we cannot rule out the
possibility of residual confounding by unmeasured
confounders. Also, we acknowledge potential misclas-
siﬁcation about kidney disease etiology, severity, and
duration of renal insufﬁciency. Additional limitations
include potential selection bias due to missing data,
ﬁnally the inability to generalize beyond the group SLK
and LTA patients who have similar PSs. On the other
hand, we have used a relatively large sample size,
carefully stratiﬁed groups based on Scr and dialysis
status at listing and transplant, and balanced covariates
using the PS matching.
In conclusion, survival beneﬁt with SLK is signiﬁ-
cantly affected by pretransplant dialysis exposure.
Donor quality strongly affects this beneﬁt, and these
data fail to support the use of kidney allografts with
L-DRI $ 1.5 in SLK recipients.
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